RxDoctor Payments Data

Tiffini Reedy

Adult Health · Fall River, MANPI 1891128708

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,257 of the $58,116 with a category attached, or 84.8%. Teva Pharmaceuticals USA, Inc. accounts for 95.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $55,328, more than ten times the $562 reported in 2021. Among adult health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,116in general payments, 2019–2025

Across 220 payments — averaging $264.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$55K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$882
  • Johnson & Johnson$794
  • Otsuka America Pharmaceutical, Inc.$656
  • Alkermes, Inc.$153
  • E.r. Squibb & Sons, L.L.C.$70
  • plus $88 from 2 others

What the payments were for

  • Consulting fees$3301%
  • Speaking & faculty fees$49,25785%
  • Travel & lodging$3,5926%
  • Food & beverage$4,6618%
  • Education$2760%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,116 in reported general payments places this provider in the 95th percentile of 671 adult health providers in Massachusetts.

See all adult health providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate141$443,081
AustedoDeutetrabenazine67$367,706
Invega TrinzaPaliperidone Palmitate13$119,409
Abilify MaintenaAripiprazole23$67,030
Abilify AsimtufiiAripiprazole12$64,657
Clozapine317$10,360
Aripiprazole111$8,533
Divalproex Sodium ErDivalproex Sodium181$4,760
Atomoxetine Hcl50$2,335
Olanzapine128$2,249
Prazosin Hcl96$1,642
Lithium Carbonate ErLithium Carbonate75$1,431
Risperidone134$1,429
Perphenazine12$1,424
Benztropine Mesylate122$1,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$794$562,490154 claims
Teva Pharmaceuticals USA, Inc.Austedo$55,475$367,70667 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii$656$131,68735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 671 adult health providers in Massachusetts.

Other adult health in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →